ArticleFrontiers in pharmacology2026
Serum metabolomics identifies GPC depletion in hepatic encephalopathy and its therapeutic potential for cognitive impairment.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic encephalopathy (HE), a common neurological complication in end-stage cirrhosis, is a complex disorder whose molecular pathogenesis has yet to be fully elucidated. Metabolomics studies provide novel insights into elucidating the pathological mechanisms of HE. This study aims to screen serum differential metabolites in cirrhosis and HE patients using metabolomics technology, with particular focus on validating the therapeutic effects of key metabolites on HE-associated cognitive dysfunction and its underlying mechanisms. Methods: This study was designed to first enroll 20-30 subjects per group (including healthy controls, cirrhosis patients, and HE patients) for serum untargeted metabolomic analysis using liquid chromatography-tandem mass spectrometry technology, combined with multivariate statistical analysis and pathway enrichment methods to identify key metabolites. This study established five experimental rat groups and developed a HE rat model via modified common bile duct ligation to evaluate the effects of key metabolite supplementation on cognitive function, while simultaneously assessing therapeutic outcomes through histopathological examination and ultrastructural observations. Results: A total of 2,375 metabolites were identified by metabolomic analysis. Comprehensive analysis screened five differentially expressed metabolites (including sn-glycero-3-phosphocholine (GPC)) significantly associated with disease progression, with GPC prioritized for subsequent validation of its effects on cognitive function in HE. The results demonstrated that GPC supplementation notably improved HE rats' spatial working memory and motor ability, while alleviating hepatic inflammatory infiltration and blood-brain barrier damage. Conclusion: This study is the first to discover and confirm the protective effect of GPC in improving cognitive dysfunction in HE, and the mechanism may be related to preserving the integrity of the blood-brain barrier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.